公开(公告)号：US12048699B2

公开(公告)日：2024-07-30

申请号：US17252400

申请日：2019-06-18

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Akihiro Ohashi ,  Kenichi Iwai ,  Tadahiro Nambu ,  Kazunori Yamanaka ,  Kentaro Otake ,  Huifeng Niu ,  Hyunjin Shin ,  Erik Michael Koenig

IPC: A61K31/519 ,  A61P35/00 ,  C12Q1/6886

CPC classification number: A61K31/519 ,  A61P35/00 ,  C12Q1/6886 ,  C12Q2600/106

Abstract: The present disclosure relates to methods useful for determining whether to treat cancer in a patient, and treating cancer in a patient, by administering a therapeutically effective amount of Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof.

公开(公告)号：US20220323443A1

公开(公告)日：2022-10-13

申请号：US17627857

申请日：2020-07-17

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Akihiro Ohashi ,  Kenichi Iwai ,  Tadahiro Nambu ,  Jie Yu ,  Kurt Eng ,  Michael Joseph Kuranda ,  Kazuho Nishimura ,  Cong Li

IPC: A61K31/519 ,  A61K31/555 ,  A61K45/06 ,  A61P35/00

Abstract: The present disclosure relates to the treatment of cancer using a combination therapy comprising Compound 1 and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof, and a second therapy.

公开(公告)号：US11155879B2

公开(公告)日：2021-10-26

申请号：US16490143

申请日：2017-03-01

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Akihiro Ohashi ,  Kenichi Iwai ,  Tadahiro Nambu ,  Ryo Dairiki ,  Yuko Ishii

IPC: C12Q1/6886 ,  A61P35/00 ,  A61K31/519

Abstract: The present invention relates to a method of predicting the likelihood that a patient will respond therapeutically to a pancreatic cancer treatment comprising the administration of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one (Compound 1) and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof, comprising the steps of: STEP (1): determining a KRAS gene mutation status of a sample from a patient, and STEP (2): predicting an increased likelihood that the patient will respond therapeutically to the pancreatic cancer treatment if the patient has the presence of KRAS gene mutation(s), and to methods of treating pancreatic cancer.

公开(公告)号：US20200010904A1

公开(公告)日：2020-01-09

申请号：US16490143

申请日：2017-03-01

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Akihiro Ohashi ,  Kenichi Iwai ,  Tadahiro Nambu ,  Ryo Dairiki ,  Yuko Ishil

IPC: C12Q1/6886 ,  A61P35/00 ,  A61K31/519

Abstract: The present invention relates to a method of predicting the likelihood that a patient will respond therapeutically to a pancreatic cancer treatment comprising the administration of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one (Compound 1) and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof, comprising the steps of: STEP (1): determining a KRAS gene mutation status of a sample from a patient, and STEP (2): predicting an increased likelihood that the patient will respond therapeutically to the pancreatic cancer treatment if the patient has the presence of KRAS gene mutation(s), and to methods of treating pancreatic cancer.